Hyperactivity News and Research

RSS

NeuroSigma receives FDA approval to begin Phase III trial of Monarch eTNS System for epilepsy

NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration of its Investigational Device Exemption application to commence a Phase III pivotal trial of the Monarch eTNS System for treatment of drug resistant epilepsy.

30 Jul 2013

Manchester scientists treat fatal genetic brain disease using stem cell gene therapy

Scientists from The University of Manchester have used stem cell gene therapy to treat a fatal genetic brain disease in mice for the first time.

From The University of Manchester 25 Jul 2013

Stem cell-based epilepsy approach may help in search for better medicines to treat seizure disorders

A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.

25 Jul 2013

NIH awards $1.7M grant to develop effective treatments for brain disorders

Ten percent of Americans experience a seizure in their lifetime, with three million diagnosed with epilepsy, a chronic neurological disorder. Anticonvulsant medications can mitigate the hyperactivity of neurons that leads to seizures, but not without severe side effects, including cognitive impairment.

23 Jul 2013

Breastfed children less likely to develop ADHD later in life

We know that breastfeeding has a positive impact on child development and health -including protection against illness. Now researchers from Tel Aviv University have shown that breastfeeding could also help protect against Attention Deficit/Hyperactivity Disorder (ADHD), the most commonly diagnosed neurobehavioral disorder in children and adolescents.

23 Jul 2013

Single dose of methylphenidate can reduce risk of falls among elderly adults

Ben-Gurion University of the Negev researchers have discovered that a single dose of methylphenidate, used to treat Attention Deficit Hyperactivity Disorder and narcolepsy, helps to improve balance control during walking, hence reducing the risk of falls among elderly adults.

18 Jul 2013

Hyperactivity due to ADHD are associated with worse prognosis in patients with eating disorders

A study made with 191 patients reveal that symptoms of hyperactivity due to the deficit of attention and hyperactivity disorder (ADHD) are associated with more impulsivity and more severity, and probably a worse prognosis in patients with eating disorders.

11 Jul 2013

Children with SPD have quantifiable differences in brain structure, reveals study

In a groundbreaking new study from UC San Francisco, researchers have found that children affected with sensory processing disorders (SPD) have quantifiable differences in brain structure, showing a biological basis for the disease that sets it apart from other neurodevelopmental disorders.

10 Jul 2013

Multimodal neuroimaging approach helps study structural and functional abnormalities in brain

Major depressive disorder is associated with a dysregulation of brain regions including the prefrontal cortex and limbic system. The relationship between structural and functional abnormalities in these brain regions in depressed patients is far from clear. However, both types of changes are assumed to underlie the symptoms of this disorder.

9 Jul 2013

Researchers identify structural anomalies that may increase risk of ADHD in premature newborns

In the first study of its kind, Natasha Leporé, PhD, and colleagues have pinpointed structural anomalies in the developing brain that may increase the risk of cognitive disabilities, such as frontal executive dysfunction and attention deficit hyperactivity disorder, in premature newborns.

6 Jul 2013

Gene therapy developed by UAB cures pediatric Sanfilippo Syndrome A in animal models

A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.

3 Jul 2013

Ritalin helps improve brain function in cocaine addiction

A single dose of a commonly-prescribed attention deficit hyperactivity disorder drug helps improve brain function in cocaine addiction, according to an imaging study conducted by researchers from the Icahn School of Medicine at Mount Sinai.

28 Jun 2013

Prader-Willi syndrome results in dysregulation of circadian and metabolic genes

Researchers with the UC Davis MIND Institute and Agilent Laboratories have found that Prader-Willi syndrome - a genetic disorder best known for causing an insatiable appetite that can lead to morbid obesity - is associated with the loss of non-coding RNAs, resulting in the dysregulation of circadian and metabolic genes, accelerated energy expenditure and metabolic differences during sleep.

26 Jun 2013

Study: Despite struggles with poverty, more children getting health insurance

Families in the United States are making gains in education and health, two key factors in their overall well-being, a report released on Monday showed, adding to data that suggests the U.S. economy is slowly rebounding from the 2007-2009 recession. Still, the latest findings on the state of U.S. children and their parents by the Annie E. Casey Foundation found many families continue to struggle ... Most states also saw more children with health insurance, improvements in birth weights, and fewer youth deaths between 2005 and 2011, it said (Heavey, 6/24).

26 Jun 2013

Researchers examine effect of ADHD in children recovering from mild traumatic brain injury

Researchers at Children's Hospital of Pittsburgh, the University of Pittsburgh, and the University of Chicago have found that children with attention deficit hyperactivity disorder are more likely to demonstrate a moderate disability after sustaining a mild traumatic brain injury than children without ADHD.

26 Jun 2013

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.

25 Jun 2013

NeuroSigma's Monarch eTNS System to make Canadian debut at 30th International Epilepsy Congress

NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.

21 Jun 2013

Researchers discover a rational source of pain in skin of patients with fibromyalgia

Fibromyalgia, a painful condition affecting approximately 10 million people in the U.S., is not imaginary after all, as some doctors have believed. A discovery, published this month in PAIN MEDICINE (the journal of the American Academy of Pain Medicine), clearly now demonstrates that fibromyalgia may have a rational biological basis located in the skin.

19 Jun 2013

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.

13 Jun 2013

Optogenetics: A promising technique for treatment of obsessive-compulsive disorders

By applying light stimulation to highly specific neurons in the brain, the researchers managed to re-establish normal behaviour in mice that had beforehand presented pathological repetitive behaviour similar to that observed in human patients suffering from obsessive-compulsive disorders.

10 Jun 2013

Hyperactivity News and Research

NeuroSigma receives FDA approval to begin Phase III trial of Monarch eTNS System for epilepsy

Manchester scientists treat fatal genetic brain disease using stem cell gene therapy

Stem cell-based epilepsy approach may help in search for better medicines to treat seizure disorders

NIH awards $1.7M grant to develop effective treatments for brain disorders

Breastfed children less likely to develop ADHD later in life

Single dose of methylphenidate can reduce risk of falls among elderly adults

Hyperactivity due to ADHD are associated with worse prognosis in patients with eating disorders

Children with SPD have quantifiable differences in brain structure, reveals study

Multimodal neuroimaging approach helps study structural and functional abnormalities in brain

Researchers identify structural anomalies that may increase risk of ADHD in premature newborns

Gene therapy developed by UAB cures pediatric Sanfilippo Syndrome A in animal models

Ritalin helps improve brain function in cocaine addiction

Prader-Willi syndrome results in dysregulation of circadian and metabolic genes

Study: Despite struggles with poverty, more children getting health insurance

Researchers examine effect of ADHD in children recovering from mild traumatic brain injury

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

NeuroSigma's Monarch eTNS System to make Canadian debut at 30th International Epilepsy Congress

Researchers discover a rational source of pain in skin of patients with fibromyalgia

NACC recommendations address established pain therapies and preview potential future advances

Optogenetics: A promising technique for treatment of obsessive-compulsive disorders

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News